CUSTOpharm, Inc. announces the creation of CUSTOpharm Development Company and CUSTOpharm Regulatory Services - Action News 5 - Memphis, Tennessee

CUSTOpharm, Inc. announces the creation of CUSTOpharm Development Company and CUSTOpharm Regulatory Services

  • HealthMore>>

  • FDA to propose e-cigarette regulations

    FDA to propose e-cigarette regulations

    © FDA© FDA
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.More >>
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.More >>
  • People seek out health info when famous person dies

    People seek out health info when famous person dies

    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
  • 1 in 13 U.S. schoolkids takes psych meds

    1 in 13 U.S. schoolkids takes psych meds

    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.More >>
    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE CUSTOpharm, Inc.

SAN DIEGO, Jan. 31, 2014 /PRNewswire/ -- CUSTOpharm, Inc. is pleased to announce the creation of two specialty divisions focusing on the two primary focuses of the company since its inception.  "The creation of the development and regulatory group as two free standing organizations will allow us to serve our customers better and focus on the ever changing landscape of the FDA," said Dave McCleary, President of the CUSTOpharm Development Company.   The Development Company will reside within our 7,500 sq. ft. laboratory space in Carlsbad and continue to focus on the development of injectable products.  The Regulatory Group is relocating to a new office in Del Mar.  "Since the opening of our laboratories in 2012, we have experienced significant growth in both product development and regulatory.  With the two specialty groups we will be able to continue growing and provide excellent services to our customers," said Fred Defesche, President of CUSTOpharm Regulatory Services.

(Logo: http://photos.prnewswire.com/prnh/20140113/MM45360LOGO)

About CUSTOpharm, Inc.
CUSTOpharm is a leading service provider in the areas of product development and regulatory affairs.  The product development focuses on the development of generic injectable, nasal and ophthalmic dosage forms.  The regulatory activities have pioneered and kept up with the ever changing regulatory landscape by transitioning to eCTD submissions in 2004 and moving to the gateway in 2008.  The regulatory activities focus on submissions in the United States and Canada.  We have filed more than 200 original applications and file more than 100 submissions per year. For more information, please visit http://www.custopharm.com

Media Contacts:

Fred Defesche
(760) 481-7811
fdefesche@custopharm.com

Dave McCleary
(760) 481-7590
dmccleary@custopharm.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow